Christopher Su

Dr. Christopher Su

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
PRPraful Ravi
Praful Ravi
CMCharlene Mantia
Charlene Mantia
CSChristopher Su
Christopher Su
KSKarl Sorenson
Karl Sorenson
DEDean Elhag
Dean Elhag
TCToni K. Choueiri
Toni K. Choueiri
Over the past 5 years, several immune checkpoint inhibitors (ICIs) have been approved for the treatment of metastatic renal cell carcinoma (mRCC). These include nivolumab, either alone or in combination with ipilimumab, as well as pembrolizumab and avelumab, both in combination with axitinib, a vascular endothelial growth factor-directed tyrosine kinase inhibitor. These therapies produce response rates of 40% to 60%, and median overall survival now approaches 4 years in patients with intermediate or poor risk treated with ipilimumab and nivolumab.1,2

9 December 2021 in Cancer
Verified
Journal Article
Closed access
PDF file
VKVadim S Koshkin
Vadim S Koshkin
NHNicholas Henderson
Nicholas Henderson
MJMarihella James
Marihella James
DNDivya Natesan
Divya Natesan
DFDory Freeman
Dory Freeman
AAAjjai S. Alva
Ajjai S. Alva

23 February 2024 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
RBRahul Banerjee
Rahul Banerjee
ACAndrew J. Cowan
Andrew J. Cowan
MOMarivel Ortega
Marivel Ortega
CMConstance Missimer
Constance Missimer
PCPaul A. Carpenter
Paul A. Carpenter
CSChristopher Su
Christopher Su

2 January 2014 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
PDF file
CSChristopher Su
Christopher Su
RMRyan D. McMahan
Ryan D. McMahan
BWBrie A. Williams
Brie A. Williams
RSRashmi K. Sharma
Rashmi K. Sharma
RSRebecca L. Sudore
Rebecca L. Sudore

22 July 2021 in JCO Precision Oncology
Verified
Journal Article
Closed access
FTFadi Taza
Fadi Taza
AHAlbert E. Holler
Albert E. Holler
WFWei Fu
Wei Fu
HWHao Wang
Hao Wang
NANabil Adra
Nabil Adra
Emmanuel S. AntonarakisEmmanuel S. Antonarakis
Emmanuel S. Antonarakis
PURPOSE: Two poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and rucaparib) are US Food and Drug Administration–approved for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring BRCA1/ 2 mutations, but the relative efficacy of PARP inhibition in BRCA1- versus BRCA2-altered mCRPC is understudied.METHODS: We conducted a multicenter retrospective analysis involving 12 sites. We collected genomic and clinical data from 123 patients with BRCA1/ 2-altered mCRPC who were treated with PARP inhibitors. The primary efficacy end point was the prostate-specific antigen (PSA) response (≥ 50% PSA decline) rate. Secondary end points were PSA progression-free survival (PSA-PFS), clinical or radiographic PFS, and overall survival. We compared clinical outcomes, and other genomic characteristics, among BRCA1- versus BRCA2-altered mCRPC.RESULTS: A total of 123 patients (13 BRCA1 and 110 BRCA2) were included. PARP inhibitors used were olaparib (n = 116), rucaparib (n = 3), talazoparib (n = 2), and veliparib (n = 2). At diagnosis, 72% of patients had Gleason 8-10 disease. BRCA1 patients were more likely to have metastatic disease at presentation (69% v 37%; P = .04). Age, baseline PSA, metastatic distribution, and types of previous systemic therapies were similar between groups. There were equal proportions of germline mutations (51% v 46%; P = .78) in both groups. BRCA1 patients had more monoallelic (56% v 41%; P = .49) and concurrent TP53 (55% v 36%; P = .32) mutations. PSA50responses in BRCA1- versus BRCA2-altered patients were 23% versus 63%, respectively ( P = .01). BRCA2 patients achieved longer PSA-PFS (HR, 1.94; 95% CI, 0.92 to 4.09; P = .08), PFS (HR, 2.08; 95% CI, 0.99 to 4.40; P = .05), and overall survival (HR, 3.01; 95% CI, 1.32 to 6.83; P = .008). Biallelic (compared with monoallelic) mutations, truncating (compared with missense) mutations, and absence of a concurrent TP53 mutation were associated with PARP inhibitor sensitivity.CONCLUSION: PARP inhibitor efficacy is diminished in BRCA1- versus BRCA2-altered mCRPC. This is not due to an imbalance in germline mutations but might be related to more monoallelic mutations and/or concurrent TP53 alterations in the BRCA1 group.

1 March 2020 in Clinical Lung Cancer
Verified
Journal Article
Closed access
HCHaiying Cheng
Haiying Cheng
HHH. Dean Hosgood
H. Dean Hosgood
LDLei Deng
Lei Deng
KYKenny Ye
Kenny Ye
CSChristopher Su
Christopher Su
RPRoman Perez-Soler
Roman Perez-Soler